nicorandil has been researched along with Disease Exacerbation in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asakura, M; Kitakaze, M | 1 |
| Johnson, RJ; Kitagawa, W; Klawitter, J; Lanaspa, MA; Makino, H; Mathieson, PW; Miyazaki, M; Nakagawa, T; Rivard, CJ; Saleem, MA; Schreiner, GF; Tanabe, K | 1 |
| Johnson, RJ; Kitagawa, W; Nakagawa, T; Schreiner, GF; Tamura, Y; Tanabe, K; Uchida, S | 1 |
| Higgins, CB; Saeed, M; Schalla, S | 1 |
| Akutsu, H; Funada, J; Ohtani, T; Sato, M; Sekiya, M; Watanabe, K | 1 |
| Aarsland, T; Ahmadi, NS; Dickstein, K; Hall, C; Kvaløy, JT; Larsen, AI | 1 |
2 trial(s) available for nicorandil and Disease Exacerbation
| Article | Year |
|---|---|
Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis.
Topics: Administration, Oral; Arteriosclerosis; Brachial Artery; Disease Progression; Endothelium, Vascular; Female; Humans; Isosorbide Dinitrate; Male; Middle Aged; Nicorandil; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation; Vasodilator Agents | 2005 |
The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure.
Topics: Cardiac Output, Low; Cross-Over Studies; Disease Progression; Female; Humans; Male; Middle Aged; Natriuretic Peptides; Nicorandil; Nitroglycerin; Peptide Fragments; Radioimmunoassay; Stroke Volume; Time Factors; Vasoconstriction; Vasodilation; Vasodilator Agents | 2006 |
4 other study(ies) available for nicorandil and Disease Exacerbation
| Article | Year |
|---|---|
Cardioprotection in the clinical setting-lessons from J-WIND studies.
Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Disease Progression; Heart Failure; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Nicorandil; Randomized Controlled Trials as Topic; Risk Factors; Vasodilator Agents | 2010 |
Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.
Topics: Animals; Antioxidants; Apoptosis; Blood Pressure; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicorandil; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Oxidative Stress; Podocytes; Reactive Oxygen Species; Severity of Illness Index; Streptozocin | 2012 |
Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages.
Topics: Albuminuria; Animals; ATP-Binding Cassette Transporters; Blotting, Western; Cells, Cultured; Disease Progression; Immunohistochemistry; KATP Channels; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Macrophages; Male; Mice; Nephritis, Interstitial; Nicorandil; Nitric Oxide; Oxidative Stress; Paraffin Embedding; Potassium Channels, Inwardly Rectifying; Rats; Rats, Sprague-Dawley; Receptors, Drug; Sulfonylurea Receptors; Xanthine Oxidase | 2012 |
Long-term oral treatment with nicorandil prevents the progression of left ventricular hypertrophy and preserves viability.
Topics: Administration, Oral; Animals; Disease Progression; Female; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Nicorandil; Rats; Rats, Sprague-Dawley; Time; Tissue Survival | 2005 |